Abstract
Platelets have grabbed great attention as immune cells and principal modulators of tissue remodeling besides their well-known hemostatic and vascular wall safeguarding functions. In line with this knowledge, findings indicating an excessive platelet activation have been reported in systemic sclerosis, which is an autoimmune, multisystem, fibrotic disorder. By borrowing the transcriptomic data of Nakajima et al. (GEO data repository, GSE66465) we sought a platelet contribution in immunoglobulin G4-related disease (IgG4-RD) pathogenesis, another immune-mediated, fibroinflammatory, multiorgan disease. GEO2R for class comparisons and WebGestalt for functional enrichment analyses were used. When treatment naïve IgG4-RD patients were compared with healthy controls, 268 differentially expressed genes (204 with increased and 64 with decreased expression) were detected. Enrichment analyses performed using gene ontology (Biological Process), pathway (Panther), and disease (GLAD4U) functional databases documented many significantly enriched terms relating to platelets, coagulation, and thrombosis, including “ Thrombasthenia”, “ Low on-treatment platelet reactivity”, “ High on-treatment platelet reactivity”, “ Platelet reactivity”, “ Platelet aggregation inhibition”, “ Blood platelet disorders”, “ Platelet degranulation”, “ Platelet aggregation”, and “ Platelet activation”. The enrichment ratios of these terms were found to be between 6.4 and 83.2. Together with the limited data in the relevant literature, it seems imperative to plan meticulously designed research specifically focusing on platelets’ contribution to IgG4-RD pathogenesis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The microarray expression data of the study by Nakajima et al. (Gene Expression Omnibus data repository [GEO], accession number GSE66465, accession date 9.9.2022) was used for this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
